Multivariate proportional hazards regression analysis of transplant outcomes in 510 patients with MDS treated with unrelated donor marrow transplantation
. | RR (95% CI) . | P . | Favorable . |
---|---|---|---|
Neutrophil engraftment | |||
Cell dose | 1.10 (1.03-1.18) | .006 | Higher |
Donor sex (female) | 0.76 (0.60-0.93) | .01 | Male |
Recipient sex (female) | 1.24 (1.00-1.53) | .05 | Female |
Year of infusion (1988-1993) | 0.67 (0.48-0.94) | .02 | Recent transplantation |
Acute GVHD | |||
Year of infusion (1988-1993) | 1.91 (1.21-3.02) | .0006 | Recent transplantation |
HLA-A, -B, -DRB1 match | 0.65 (0.45-0.94) | .02 | Match |
Preparative regimen | 1.73 (1.08-2.76) | .02 | No TBI |
Relapse | |||
RAEB-t | 4.92 (1.96-12.4) | .0007 | RA |
AML | 7.67 (3.03-19.4) | .0001 | RA |
Acute GVHD | 0.52 (0.29-0.95) | .03 | Grades II-IV |
Treatment-related mortality | |||
Acute GVHD | 2.52 (1.90-3.34) | .0001 | Grades 0-I |
HLA-A, -B, -DRB1 match | 0.66 (0.50-0.88) | .004 | Match |
Recipient CMV serology | 1.46 (1.13-1.89) | .004 | Negative |
Recipient age | 1.13 (1.04-1.22) | .005 | Younger |
Donor age | 1.20 (1.04-1.39) | .01 | Younger |
Overall survival | |||
Acute GVHD | 2.13 (1.66-2.74) | .0001 | Grades 0-I |
AML | 2.08 (1.46-2.97) | .0001 | RA |
RAEB-t | 1.66 (1.18-2.35) | .004 | RA |
Cell dose | 0.89 (0.83-0.96) | .003 | Higher |
Recipient CMV serology | 1.44 (1.14-1.81) | .002 | Negative |
Time to transplantation (< 9 mo) | 0.76 (0.61-0.96) | .02 | Early transplantation |
Year of infusion (1988-1993) | 1.45 (1.02-2.06) | .04 | Recent transplantation |
HLA-A, -B, -DRB1 match | 0.78 (0.60-1.00) | .05 | Match |
Disease-free survival | |||
Acute GVHD | 1.93 (1.50-2.47) | .0001 | Grades 0-I |
AML | 2.04 (1.43-2.91) | .0001 | RA |
RAEB-t | 1.71 (1.22-2.40) | .002 | RA |
Cell dose | 0.89 (0.83-0.96) | .003 | Higher |
Recipient CMV serology | 1.46 (1.16-1.84) | .001 | Negative |
Time to transplantation (< 9 mo) | 0.78 (0.62-0.98) | .03 | Early transplantation |
Year of infusion (1988-1993) | 1.43 (1.01-2.01) | .03 | Recent transplantation |
. | RR (95% CI) . | P . | Favorable . |
---|---|---|---|
Neutrophil engraftment | |||
Cell dose | 1.10 (1.03-1.18) | .006 | Higher |
Donor sex (female) | 0.76 (0.60-0.93) | .01 | Male |
Recipient sex (female) | 1.24 (1.00-1.53) | .05 | Female |
Year of infusion (1988-1993) | 0.67 (0.48-0.94) | .02 | Recent transplantation |
Acute GVHD | |||
Year of infusion (1988-1993) | 1.91 (1.21-3.02) | .0006 | Recent transplantation |
HLA-A, -B, -DRB1 match | 0.65 (0.45-0.94) | .02 | Match |
Preparative regimen | 1.73 (1.08-2.76) | .02 | No TBI |
Relapse | |||
RAEB-t | 4.92 (1.96-12.4) | .0007 | RA |
AML | 7.67 (3.03-19.4) | .0001 | RA |
Acute GVHD | 0.52 (0.29-0.95) | .03 | Grades II-IV |
Treatment-related mortality | |||
Acute GVHD | 2.52 (1.90-3.34) | .0001 | Grades 0-I |
HLA-A, -B, -DRB1 match | 0.66 (0.50-0.88) | .004 | Match |
Recipient CMV serology | 1.46 (1.13-1.89) | .004 | Negative |
Recipient age | 1.13 (1.04-1.22) | .005 | Younger |
Donor age | 1.20 (1.04-1.39) | .01 | Younger |
Overall survival | |||
Acute GVHD | 2.13 (1.66-2.74) | .0001 | Grades 0-I |
AML | 2.08 (1.46-2.97) | .0001 | RA |
RAEB-t | 1.66 (1.18-2.35) | .004 | RA |
Cell dose | 0.89 (0.83-0.96) | .003 | Higher |
Recipient CMV serology | 1.44 (1.14-1.81) | .002 | Negative |
Time to transplantation (< 9 mo) | 0.76 (0.61-0.96) | .02 | Early transplantation |
Year of infusion (1988-1993) | 1.45 (1.02-2.06) | .04 | Recent transplantation |
HLA-A, -B, -DRB1 match | 0.78 (0.60-1.00) | .05 | Match |
Disease-free survival | |||
Acute GVHD | 1.93 (1.50-2.47) | .0001 | Grades 0-I |
AML | 2.04 (1.43-2.91) | .0001 | RA |
RAEB-t | 1.71 (1.22-2.40) | .002 | RA |
Cell dose | 0.89 (0.83-0.96) | .003 | Higher |
Recipient CMV serology | 1.46 (1.16-1.84) | .001 | Negative |
Time to transplantation (< 9 mo) | 0.78 (0.62-0.98) | .03 | Early transplantation |
Year of infusion (1988-1993) | 1.43 (1.01-2.01) | .03 | Recent transplantation |